Cascadian Therapeutics

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. Cascadian Therapeutics' clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. Cascadian Therapeutics completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Company Growth (employees)
Type
Public
HQ
Seattle, US
Founded
2007
Size (employees)
57 (est)
Cascadian Therapeutics was founded in 2007 and is headquartered in Seattle, US

Cascadian Therapeutics Office Locations

Cascadian Therapeutics has an office in Seattle
Seattle, US (HQ)
500 2601 4th Ave

Cascadian Therapeutics Financials and Metrics

Cascadian Therapeutics Financials

USD

Net income (Q1, 2017)

(11.4 m)

EBIT (Q1, 2017)

(11.6 m)

Market capitalization (20-Oct-2017)

218.4 m

Closing share price (20-Oct-2017)

4.1

Cash (31-Mar-2017)

35.7 m
Cascadian Therapeutics's current market capitalization is $218.4 m.
USDFY, 2016

R&D expense

27.5 m

General and administrative expense

17.6 m

Operating expense total

45.1 m

EBIT

(64.8 m)
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

5.7 m5.8 m5.7 m5.1 m6.3 m6.4 m7.3 m8.6 m

General and administrative expense

2.4 m2.3 m2.6 m2.1 m6.6 m4.4 m3.5 m3 m

Operating expense total

8 m8.1 m8.3 m7.2 m13 m10.7 m10.8 m11.6 m

EBIT

(8 m)(8.1 m)(8.3 m)(7.2 m)(13 m)(30.5 m)(10.8 m)(11.6 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

9.3 m10.5 m27.9 m13.7 m

Current Assets

60.9 m58.9 m58 m64.5 m

PP&E

1.7 m1.6 m1.8 m1.4 m

Goodwill

2.1 m16.7 m16.7 m16.7 m
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

34.2 m13.5 m12.9 m25.3 m13.9 m51 m16.6 m35.7 m

Current Assets

82 m75 m70.8 m64.4 m48.2 m81.8 m73.1 m127.8 m

PP&E

1.7 m1.9 m1.8 m1.9 m1.7 m1.6 m1.3 m1.7 m

Goodwill

16.7 m16.7 m16.7 m16.7 m16.7 m16.7 m16.7 m16.7 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(38.8 m)(50 m)(32.6 m)(57.7 m)

Depreciation and Amortization

489 k512 k613 k642 k

Accounts Payable

(600 k)144 k(250 k)385 k

Cash From Operating Activities

(36.3 m)(48.4 m)(28.9 m)(36.8 m)
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(6.7 m)(7.9 m)(10.9 m)(4.6 m)(12.9 m)(23.5 m)(10.8 m)(11.4 m)

Accounts Payable

303 k497 k353 k389 k832 k1.3 m741 k1 m
Y, 2017

Financial Leverage

1 x
Show all financial metrics

Cascadian Therapeutics Operating Metrics

FY, 2016

Patents (US)

1

Patents (foreign)

18

Patents Licensed

222
Show all operating metrics

Cascadian Therapeutics Market Value History

Traffic Overview of Cascadian Therapeutics

Cascadian Therapeutics Company Life and Culture

You may also be interested in